The aims of this study were to determine the contribution of the AT2 receptor to the antihypertensive and regional vasodilatory effects of AT1 receptor blockade in adult spontaneously hypertensive rats (SHR), 2-kidney, 1-clip hypertensive (2K1C) rats, and sham-operated normotensive rats. Several studies have provided evidence to support the notion that the AT2 receptor may have opposing effects to those mediated by the AT 1 receptor. We therefore tested the hypothesis that the depressor and vasodilator effects of acute AT 1 receptor blockade are dependent on AT 2 receptor activation. Heart rate, mean arterial pressure, and regional hemodynamics were measured over a 4-day protocol in rats that received the following treatments in randomized order: saline vehicle, the AT1 receptor antagonist candesartan (0.1 mg/kg iv bolus), the AT 2 receptor antagonist PD-123319 (50 g ⅐ kg Ϫ1 ⅐ min Ϫ1 ), or both antagonists. Intravenous candesartan reduced mean arterial pressure in all groups of rats, and this was accompanied by renal and mesenteric vasodilation. Neither saline nor PD-123319 significantly affected these variables. Concomitant PD-123319 administration partially reversed the depressor and mesenteric vasodilator effects of candesartan in sham-operated normotensive rats but not in SHR or 2K1C rats. These data indicate that the AT2 receptor contributes to the blood pressure-lowering and mesenteric vasodilator effects of AT1 receptor blockade in the acute setting in conscious normotensive but not hypertensive rats. angiotensin receptors; candesartan; PD-123319; regional hemodynamics; hypertension; renal ANGIOTENSIN II (ANG II), the main effector peptide of the renin angiotensin system (RAS), acts at two main receptor subtypes: the AT 1 receptor and the AT 2 receptor (7). The well-known ANG II actions such as regulation of blood pressure and water and electrolyte balance have been attributed mainly to the various signal transduction pathways activated by the AT 1 receptor (7). The role of the AT 2 receptor is less well defined. There is evidence that AT 2 receptor activation may oppose effects mediated by the AT 1 receptor. For example, AT 2 receptor activation appears to inhibit AT 1 receptor-mediated vasoconstriction and cell proliferation (3, 13, 16, 33, 44, 53) .
ANGIOTENSIN II (ANG II), the main effector peptide of the renin angiotensin system (RAS), acts at two main receptor subtypes: the AT 1 receptor and the AT 2 receptor (7). The well-known ANG II actions such as regulation of blood pressure and water and electrolyte balance have been attributed mainly to the various signal transduction pathways activated by the AT 1 receptor (7) . The role of the AT 2 receptor is less well defined. There is evidence that AT 2 receptor activation may oppose effects mediated by the AT 1 receptor. For example, AT 2 receptor activation appears to inhibit AT 1 receptor-mediated vasoconstriction and cell proliferation (3, 13, 16, 33, 44, 53) .
AT 2 receptor-mediated vasodilation in vitro has been reported previously (2, 9, 11, 12, 29, 52) , and these findings are further supported by in vivo data. For example, Barber et al. (3) found that in spontaneously hypertensive rats (SHR), the AT 2 receptor agonist CGP-42112 lowered blood pressure, but only in the presence of AT 1 receptor blockade, suggesting that AT 2 receptors play a modulatory role in the regulation of arterial pressure (3) . This unmasked AT 2 receptor-mediated depressor effect of CGP-42112 was abolished by PD-123319. More recently, Li and Widdop (22) performed analogous experiments in which regional hemodynamics were measured and found that CGP-42112 evoked renal and mesenteric vasodilation in conscious SHR in the presence of AT 1 receptor blockade. Similarly, Carey et al. (5) reported that direct stimulation of the AT 2 receptor with CGP-42112 reduced arterial pressure in conscious rats and that this effect was blocked by PD-123319 (5) . Collectively, these data suggest that in SHR, direct AT 2 receptor activation causes depressor and vasodilator responses, but only when these are unmasked by the presence of an AT 1 receptor antagonist (3, 22) .
In vivo, AT 1 receptor antagonists induce increases in plasma ANG II concentration as a result of inhibition of the AT 1 receptormediated negative feedback on renin release (46) . Therefore, it has been suggested that at therapeutic doses of AT 1 receptor antagonists, endogenous ANG II may stimulate AT 2 receptors, which in turn contributes to their depressor effects (6, 8) . This hypothesis was recently extensively reviewed (51) , and it was noted that there are very few studies examining blood pressure status in this context. In a 2-kidney, 1-wrap model of renovascular hypertension, activation of the RAS has been shown to increase arterial pressure through the AT 1 receptor (40) . The antihypertensive effect of the AT 1 receptor antagonist losartan was prevented by AT 2 receptor blockade with PD-123319 and also by the use of the bradykinin B 2 receptor antagonist icatibant (40) . In addition, acute studies from the same laboratories have documented that in conscious rats, sodium depletion caused an increase in renal interstitial fluid levels of cGMP that was blocked by PD-123319 (41, 42) . Furthermore, valsartan reduced systolic blood pressure in both sodium-depleted and renovascular hypertensive rats, and this effect of valsartan was reversed by coinfusion of PD-123319 (43) . Therefore, stimulation of the AT 2 receptor by endogenous ANG II appears to contribute to the antihypertensive action of AT 1 receptor antagonists, at least in the acute setting.
Collectively, the studies described above give the general impression that in experiments in which models of increased RAS activity (e.g., renovascular hypertension, low salt) are used, AT 2 receptor-mediated vasodilatation may contribute to the antihypertensive efficacy of AT 1 receptor antagonists. However, in these studies, only systolic blood pressure was measured, which does not necessarily clearly identify the hemodynamic changes that may have occurred. Therefore, in the present study we tested the acute effects of candesartan and PD-123319 (and their combination) on regional hemodynamics in conscious normotensive rats and in renin-dependent (2-kidney, 1-clip; 2K1C) and renin-independent (SHR) hypertensive rat models. In so doing, we have tested the hypothesis that AT 2 receptor blockade would reverse the antihypertensive and regional vasodilatory effects of AT 1 receptor blockade. We also hypothesized that this AT 2 receptor component of AT 1 receptor blockade would be manifest to a greater extent in 2K1C rats than in SHR or normotensive animals. The latter hypothesis was based on the likelihood that elevated circulating levels of ANG II in 2K1C rats (35) would cause marked AT 2 receptor stimulation.
METHODS

Animals.
Male Sprague-Dawley rats (Biological Research Laboratories, Baker Heart Institute, Victoria, Australia; n ϭ 14) and SHR (Biological Research Laboratories, Austin Repatriation Medical Centre, Victoria, Australia; n ϭ 10) were used. Sprague-Dawley rats were used to establish renovascular hypertension, and SHR rats were used as an established non-renin-dependent model of hypertension. Procedures were approved by the Monash University Department of Pharmacology Animal Ethics Committee and accorded with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Establishment of hypertension. To establish 2K1C hypertension, we anesthetized Sprague-Dawley rats ϳ4 wk of age (100 -150 g) with isoflurane (1-3%; Abbott Australasia, Kurnell, Australia), and a U-shaped silver clip (0.2-mm ID) was placed on the right renal artery as described previously (23) . A sham control group of rats received similar surgical intervention except that the silver clip was not inserted. Tail-cuff systolic blood pressure (SBP) was measured in both groups at weekly intervals (NIBP controller; ADInstruments, Sydney, NSW, Australia). Only rats with SBP Ͼ160 mmHg underwent further surgery. Experiments were begun in rats ϳ3-4 wk after clipping, and after Doppler surgery (see below) was performed at ϳ10 wk of age.
Implantation of pulsed Doppler flow probes. SHR (15 wk of age), sham-operated, and 2K1C rats (9 wk of age, 300 -350 g) were anesthetized with sodium pentobarbitone (40 -60 mg/kg ip; Nembutal; Rhone Merieux, Pinkenba, QLD, Australia) supplemented as required and had pulsed Doppler flow probes implanted around the left renal and superior mesenteric arteries and distal abdominal aorta as previously described (23, 50) . After the surgery, all rats were given an intramuscular injection of terramycin/LA (0.3 mg/kg; Pfizer, Melbourne, Australia) and were housed in individual cages and maintained on the same diet.
Vascular catheterization. After at least 1 wk of recovery from implantation of Doppler probes, rats were again anesthetized with sodium pentobarbitone (40 -60 mg/kg). Doppler probe wires were retrieved, and individual signals from each probe were verified on a MacLab recording system (PowerLab; ADInstruments). The two wire leads for each probe were then soldered into a six-port microconnector (Microtech, Boothwyn, PA) under a microscope (Olympus, Tokyo, Japan). Two catheters (polyethylene tubing, 0.28-mm ID, 0.61-mm OD, Biocorp Australia, Huntingdale, Victoria, Australia) were then inserted ϳ2 cm into the right jugular vein for intravenous administration of drugs or saline, and a catheter (polyethylene tubing, 0.58-mm ID, 0.96-mm OD, Biocorp Australia) was inserted ϳ2 cm into the right carotid artery for measurement of arterial blood pressure and heart rate (HR). The catheters were then tunneled subcutaneously to emerge at the same point as the Doppler wires (posterior neck region) and were inserted through a flexible spring that was secured along with the six-port microconnector to a custom-made harness worn by the rat. All animals were then allowed a further 24-to 48-h recovery period, during which time they had free access to food and water. Arterial catheters were kept patent by a constant infusion of heparinized saline (15 IU/ml; David Bull Laboratories, Mulgrave, Victoria, Australia) at 1 ml⅐kg Ϫ1 ⅐h Ϫ1 at all times other than the acute experimental protocols.
Experimental protocol. All experiments were conducted in conscious, freely moving rats. On the day of experimentation, continuous recordings were made of phasic intra-arterial blood pressure, HR, and mean and phasic renal, mesenteric, and hindquarter blood flow. In all rats, baseline levels of cardiovascular variables were recorded initially for at least 60 min before the administration of any drug. All rats were studied over a 4-day protocol. In SHR (n ϭ 10), sham (n ϭ 7), and 2K1C rats (n ϭ 7), we tested the effects of 1) saline (0.35 ml/h iv), 2) AT 1 receptor blockade (candesartan; 0.1 mg/kg iv bolus plus saline infusion), 3) AT2 receptor blockade (PD-123319; 50 g⅐kg Ϫ1 ⅐min Ϫ1 iv), or 4) combined AT1 and AT2 receptor blockade, each on a different day. The PD-123319 infusion was commenced 60 min before the administration of candesartan. These treatments were given in a random order. Responses to an intravenous bolus of ANG II (5-25 ng/kg) were tested at baseline and at 2, 4, and 6 h after the vehicle and/or antagonist treatments. All doses were based on previous studies in our laboratory (3, (21) (22) (23) .
At the time of experimentation, all variables were displayed on a MacLab8 system (ADInstruments) interfaced with a Macintosh computer (23) . Doppler shift is an index of blood flow, whereas regional vascular conductances were calculated by dividing the appropriate mean Doppler shift signal by mean arterial pressure (MAP) (23, 50) .
Statistical analysis. Data are expressed as means Ϯ SE and were subjected to analysis of variance (ANOVA) with the computer software SYSTAT (version 9; SPSS, Chicago, IL). Changes in hemodynamic variables from pretreatment baseline, on any given treatment day, were analyzed using repeated-measures ANOVA. For comparisons between different experimental subjects, Student's unpaired t-test was used to determine whether SBP changed after sham or 2K1C surgery. ANOVA was used to determine, within each group of rats, whether baseline levels of hemodynamic variables differed before any antagonist treatment was administered. Partitioned ANOVA also allowed us to test whether baseline levels of hemodynamic variables differed in the three groups of rats. Repeated-measures ANOVA (26) was used to determine the effects and interactions of the antagonist treatments. To protect against the increased risk of a false positive inference due to compound asymmetry, P values from within-subject factors were conservatively adjusted using the Greenhouse-Geisser method (26) . Statistical significance was accepted as P Յ 0.05.
RESULTS
Tail-cuff SBP in conscious sham-operated and 2K1C rats.
SBP of sham rats remained constant (118 Ϯ 4 mmHg) over the 3-to 4-wk measurement period. In contrast, SBP of 2K1C rats rose significantly to 189 Ϯ 11 mmHg (P Ͻ 0.001) 3 wk after surgery (Fig. 1) .
Resting hemodynamics. Baseline levels of MAP, HR, and regional hemodynamic variables were similar to those ob- Fig. 1 . Tail-cuff systolic blood pressure (SBP) was recorded before (week 0) and 3 wk after surgery (clipping) in 2-kidney, 1-clip (2K1C) rats and shamoperated rats. Bars show means Ϯ SE (n ϭ 7 rats/group). ***P Ͻ 0.001 vs. respective control (paired t-test).
served previously (23) . Resting hemodynamics, averaged at the beginning of each treatment day in the three groups, are shown in Table 1 . Generally, arterial pressure was higher in the hypertensive models compared with sham normotensive rats. In SHR, there was marked generalized vasoconstriction, and this was less pronounced in 2K1C rats (Table 1) . Within each group of rats, resting levels of all hemodynamic variables did not differ according to the antagonist treatment that followed (Tables 2-4) .
Normotensive rats. In sham-operated normotensive rats, candesartan had minimal effects on HR or renal and hindquarter flows and conductances, whereas it caused an immediate marked decrease in MAP (maximum: 20 Ϯ 3 mmHg), which was accompanied by mesenteric vasodilatation (26 Ϯ 12 and 50 Ϯ 14% increases in mesenteric flow and conductance, respectively) (Fig. 2) . HR, MAP, and renal and mesenteric flows and conductances were not significantly affected by saline or PD-123319 treatment. PD-123319 decreased hindquarter flow by 25 Ϯ 7% (data not shown); however, hindquarter conductance was unaffected (Fig. 2) . When PD-123319 was coinfused with candesartan, changes in HR and renal and Data are means Ϯ SE of average values of each variable during the 60-min control period before treatments were administered. P values are as described in Table 2 .
hindquarter flows and conductances were indistinguishable from those after candesartan alone. However, coinfusion of PD-123319 abolished the depressor and mesenteric vasodilatory (increased mesenteric flow and conductance) effect of candesartan (Fig. 2) .
2K1C hypertensive rats. In 2K1C rats, candesartan had a minimal effect on HR but caused an immediate, marked decrease in MAP (maximum: 23 Ϯ 4 mmHg) (Fig. 3) , which was accompanied by renal and mesenteric vasodilatation (47 Ϯ 9 and 22 Ϯ 10% increases in conductances, respectively). Candesartan had no significant effect on hindquarter flow or conductance (Fig. 3) . HR, MAP, and renal, mesenteric, and hindquarter flows and conductances were not significantly affected by saline or PD-123319 treatment (Fig. 3) . When PD-123319 was coinfused with candesartan, HR, MAP, and regional flows and conductances were indistinguishable from those after candesartan alone (Fig. 3) .
SHR. In SHR, candesartan administration was followed by a slight, transient tachycardia (Fig. 4) . Candesartan caused an immediate, marked decrease in MAP (maximum: 27 Ϯ 5 mmHg) (Fig. 4) , which was accompanied by renal vasodilatation (28 Ϯ 4 and 49 Ϯ 8% increases in renal flow and conductance) and mesenteric vasodilatation (21 Ϯ 11% increase in mesenteric conductance). Candesartan had no significant effect on hindquarter flow or conductance (Fig. 4) . HR, MAP, and renal and hindquarter flows and conductances were not significantly affected by saline or PD-123319 treatment (Fig. 4) . However, mesenteric flow was decreased after saline (21 Ϯ 7%) and PD-123319 (25 Ϯ 8%) treatment (data not shown), although the reductions in mesenteric conductance failed to reach significance (Fig. 4) . When PD-123319 was coinfused with candesartan, HR, MAP, and regional flows and conductances were indistinguishable from those after candesartan alone (Fig. 4) .
Responses to ANG II. In each group, responses to an intravenous bolus of ANG II (5-25 ng/kg) were measured before and after drug administration to determine the level of AT 1 blockade induced by candesartan (Figs. 5-7) . In all sham normotensive and SHR rats, a 5 ng/kg dose of ANG II was sufficient to induce a pressor response of ϳ20 mmHg. However, in three of the seven 2K1C rats, a 25 ng/kg dose of ANG II was required to induce a pressor response of ϳ20 mmHg. These pressor responses to ANG II were accompanied by marked renal and mesenteric vasoconstriction (decreased conductances) and variable effects on the hindquarters (Figs. 5-7) . The vasoconstrictor effects of ANG II were markedly reduced (usually by 70 -90%) by candesartan alone and in combination with PD-123319, whereas the regional hemodynamic effect of ANG II was reproducible over 6 h in the rats treated with saline.
DISCUSSION
In the present study, we examined whether the depressor and regional vasodilator effects of acute AT 1 receptor blockade could be reversed with acute AT 2 receptor antagonism. Adult male SHR were used as a model of genetic hypertension, 2K1C rats were Fig. 2 . Effects of AT1 and AT2 receptor blockade on systemic and regional hemodynamics in normotensive rats. PD-123319 (PD; 50 g ⅐ kg Ϫ1 ⅐ min Ϫ1 iv) or saline commenced 60 min before candesartan (Cand; 0.1 mg/kg iv) and continued for 7 h of the experiment. HR, heart rate; MAP, mean arterial pressure; Ren Cond, renal conductance; Mes Cond, mesenteric conductance; HQ Cond; hindquarter conductance. Symbols and error bars represent means Ϯ SE, respectively, of the changes in HR, MAP, and renal, mesenteric, and hindquarter conductances during the experimental period. *P Ͻ 0.05 and ***P Ͻ 0.001, overall effect vs. baseline (ANOVA). #P Ͻ 0.05, treatment-time interaction between candesartan and candesartan ϩ PD-123319 (ANOVA). Fig. 3 . Effects of AT1 and AT2 receptor blockade on systemic and regional hemodynamics in 2K1C rats. PD-123319 (50 g ⅐ kg Ϫ1 ⅐ min Ϫ1 iv) or saline commenced 60 min before candesartan (0.1 mg/kg iv) and continued for 7 h of the experiment. Symbols and error bars represent means Ϯ SE, respectively, of the changes in HR, MAP, and renal, mesenteric, and hindquarter conductances during the experimental period. *P Ͻ 0.05 and ***P Ͻ 0.001, overall effect vs. baseline (ANOVA). used as a renin-dependent model of hypertension, and shamoperated rats were used as their normotensive controls. To our knowledge, this is the first study investigating the potential role of AT 2 receptors in regional hemodynamic responses to acute AT 1 receptor blockade in a range of conscious rat models.
The major new finding from the present study was that the blood pressure-lowering effect of AT 1 receptor antagonism was reversed by PD-123319 in normotensive rats but not in SHR or 2K1C hypertensive rats. We had hypothesized that AT 2 receptor-mediated vasodilatation might contribute to the hemodynamic profile of AT 1 receptor antagonists and that the contribution was likely to be greater in hypertensive rats, particularly 2K1C rats, because of elevated ANG II levels (35) . We now reject this hypothesis, because PD-123319 did not reverse the antihypertensive or vasodilator responses to candesartan in 2K1C or SHR rats.
In the present study, AT 1 receptor blockade caused reductions in blood pressure in all rat models. This was accompanied by marked renal vasodilatation in the hypertensive rat models but by an inconsistent effect in this vascular bed in normotensive rats. This observation is consistent with the findings of previous studies in our laboratory (21, 23) , in which candesartan evoked more marked renal vasodilatation in hypertensive than normotensive rats. Candesartan also caused mesenteric dilation in both normotensive and hypertensive rats, with little effect in the hindquarter circulation. Again, these findings are consistent with those of previous studies in our laboratory (21) (22) (23) , in which mesenteric vasodilatation, induced by candesartan, was more marked than vasodilatation in the hindquarter vascular bed. However, in hypertensive rats, PD-123319 failed to alter the antihypertensive and renal vasodilator responses to candesartan, indicating no role of the AT 2 receptor in mediating vasodilatation initiated by AT 1 receptor blockade under these experimental conditions. Similarly, Nakamura et al. (34) reported minimal reversal (ϳ8 mmHg) by PD-123319 of the antihypertensive effect (ϳ46 mmHg) of losartan in SHR, an effect that is not inconsistent with our observations in SHR. The dose of PD-123319 used in the present study was shown previously to block the vasodilator effects of the AT 2 receptor agonist CGP-42112 in vivo (3, 22) .
The lack of reversal by PD-123319 of the depressor response of AT 1 receptor blockade is in marked contrast to the results reported by Siragy and colleagues (40, 43) , who found that losartan or valsartan reduced SBP in both sodium-depleted and renovascular hypertensive rats, and this antihypertensive effect was reversed by coinfusion of PD-123319. The reasons for the discrepancies between the current and previous studies are not immediately obvious but possibly could relate to different models and experimental conditions. AT 2 receptor expression varies with age, being highly expressed in fetal tissue but immediately declining after birth to a lower level of expression in vasculature that exists in adulthood (see Ref. 51) . However, age is not likely to be a factor in the current study, because male normotensive and 2K1C rats were the same age (10 wk), which was not dissimilar to the age of rats used by Siragy and colleagues (40, 43) . However, these authors used a renal wrap model of renovascular hypertension or sodium depletion and measured noninvasive SBP, which differs from invasive blood pressure measurements in the present study. They also measured intrarenal hemodynamics in the anesthetized state and found that PD-123319 prevented the increase in renal cortical blood flow induced by losartan administration, although the effect on total renal blood flow was not reported (40) . On the other hand, we (10) recently reported that PD-123319 did not affect responses of renal or cortical blood flow to candesartan.
In the present study, AT 2 receptor-mediated mesenteric vasodilation was implicated in normotensive rats, because administration of the AT 2 receptor antagonist reversed the AT 1 receptor antagonist-induced increase in mesenteric blood flow. Thus acute AT 2 receptor activation appears to exert vasodilator effects in the mesenteric circulation and contribute to the blood pressure-lowering efficacy of AT 1 receptor antagonists in normotensive but not hypertensive rats, at least in the acute setting. These data are consistent with the findings of Matrougui and colleagues (28, 29) , who reported that AT 2 receptors mediate relaxation of isolated mesenteric arteries of WistarKyoto (WKY) but not SHR rats. This lack of AT 2 receptormediated vasodilation in SHR was postulated to be due to impaired nitric oxide-and prostaglandin-mediated responses to flow in resistance arteries of hypertensive rats (30) . Given that AT 2 receptors stimulate vasodilation by an autocrine cascade including bradykinin, nitric oxide, and cGMP, the lack of effect of AT 2 receptor blockade in hypertensive rats in the present study also may be due to impaired signaling pathways, as is known to occur with nitric oxide in the hypertensive state (1, 20, 38) , and most likely involves increased oxidative stress reducing nitric oxide bioavailability (49) . These functional data do not exactly correspond with studies in which vascular cGMP production is measured, since Gohlke et al. (14) first reported that AT 2 receptor stimulation increased cGMP in aortas obtained from SHR. On the other hand, AT 2 receptor stimulation in aortas obtained from normotensive rats has been reported to exert no effect (37) or increased cGMP production (17) .
Furthermore, the situation is much more complex in vivo, because direct AT 2 receptor stimulation by exogenous CGP-42112 does, in fact, cause vasodilation in SHR but not WKY rats, because AT 2 receptor-mediated vasodilation occurred in response to infusion with CGP-42112, but only in the presence of AT 1 receptor blockade (3, 22) . Therefore, there appears to be a difference between the effects of acute endogenous AT 2 receptor stimulation during AT 1 receptor blockade and the effects of acute exogenous AT 2 receptor stimulation with the synthetic peptide CGP-42112.
In the present study, bolus injections of ANG II were obtained to determine the level of AT 1 receptor blockade induced by candesartan. ANG II caused marked increases in MAP that were associated with decreases in renal and mesenteric conductance and variable responses of hindquarter conductance, as previously reported (21) (22) (23) 50) . However, in 2K1C rats, pressor responses to ANG II were less than those in SHR or normotensive rats, with higher doses of ANG II sometimes required to match pressor responses. The most likely explanation for this is that the vasculature is less sensitive to ANG II, because circulating (36) and intrarenal levels (15) of ANG II are elevated in rats with 2K1C hypertension. In any case, candesartan alone or in combination with PD-123319 markedly reduced ANG II-mediated vasoconstriction. Indeed, the effects of candesartan were very prolonged, similar to those we have noted previously, even from a single intravenous dose (21) (22) (23) 50) . In vitro, PD-123319 has been shown to potentiate contractile responses to ANG II (2, 16, 31, 53) , suggesting that the activation of the AT 2 receptor is linked to a vasodilator mechanism that opposes vasoconstriction induced by AT 1 receptor activation. Potentiation of ANG II pressor responses in PD-123319-treated animals has occasionally been seen in vivo (32) , although usually this is not seen (22, 27) , as was the case in the present study. Furthermore, there was little evidence of AT 2 receptor-mediated vasodilation evoked by exogenous ANG II (in the presence of candesartan), which presumably indicates that bolus administration of ANG II was less effective than longer infusions designed to stimulate AT 2 receptors (3, 22) .
Collectively, the results of the present study indicate that acutely, AT 2 receptor activation contributes to the acute hemodynamic effects of AT 1 receptor blockade in conscious normotensive, but not hypertensive, rats. However, this is clearly not the case with respect to cardiovascular structural remodeling, particularly under certain pathological conditions in which it is known that AT 2 receptors are upregulated (4, 18, 25, 39, 47) . In this context, AT 2 receptor stimulation has an important role in the cardiovascular protective effects seen with chronic treatment with AT 1 receptor antagonists, because chronic administration of PD-123319 reversed the decreases in cardiac fibrosis and vascular remodeling observed with AT 1 receptor antagonists in rat models of hypertension (SHR), heart failure, and senescence (19, 24, 45, 48) . Therefore, the results of these studies indicate a role for the AT 2 receptor in mediating the beneficial structural effects of AT 1 receptor antagonist therapy, although there appears to be minimal influence of the AT 2 receptor on sartan-mediated changes in arterial pressure under both acute (present study) and chronic (19, 24, 45, 48) pathological conditions. However, a role for an AT 2 receptor-mediated contribution to the acute hemodynamic effect of sartan compounds in normotensive rats was established. 
